There is substantial evidence for bioenergetic defects in Huntington's disease (HD). Creatine administration increases brain phosphocreatine levels and it stabilizes the mitochondrial permeability transition. We examined the effects of creatine administration in a transgenic mouse model of HD produced by 82 polyglutamine repeats in a 171 amino acid N-terminal fragment of huntingtin (N171-82Q). Dietary supplementation of 2% creatine significantly improved survival, slowed the development of motor symptoms, and delayed the onset of weight loss. Creatine lessened brain atrophy and the formation of intranuclear inclusions, attenuated reductions in striatal N-acetylaspartate as assessed by NMR spectroscopy, and delayed the development of hyperglycemia. These results are similar to those observed using dietary creatine supplementation in the R6/2 transgenic mouse model of HD and provide further evidence that creatine may exert therapeutic effects in HD.
INTRODUCTION
Huntington's disease (HD) is an autosomal dominant inherited neurodegenerative disorder characterized by a progressive development of motor, psychiatric, and cognitive symptoms (Hersch and Ferrante, 1997; Kowall et al., 1999) . The onset of HD is usually in mid-life with a mean survival of 15-20 years after onset. The HD gene mutation is an expanded unstable CAG/polyglutamine repeat in huntingtin, a protein of unknown function with a relative molecular weight of 350,000 (The Huntington's Disease Collaborative Research Group, 1993) . Normal individuals possess a repeat length of 6 -35 glutamines, whereas HD is present when alleles of more than 36 repeats are inherited. The age of onset and the severity of the disease are correlated with the length of the CAG expansion (Andrew et al., 1993; Duyao et al., 1993; Snell et al., 1993) .
Although the discovery of the HD gene defect has played an important role in understanding the pathogenesis of the disease, the pathogenetic mechanism is
